Loading...
Loading...
CRVS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 9.9M |
| Operating I/L | -9.9M |
| Other Income/Expense | 25.1M |
| Interest Income | 0.5M |
| Pretax | 15.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 15.2M |
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in immuno-oncology therapies. Its lead product candidate, Mupadolimab (CPI-006), is an anti-CD73 monoclonal antibody in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, both in clinical trials for various cancers. Additionally, it has preclinical stage products including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis.
